Cingulate Q2 EPS Increased by Ascendiant Capital Markets

Cingulate Inc. (NASDAQ:CING) – Ascendiant Capital Markets raised their Q2 2026 earnings estimates for shares of Cingulate in a research note issued on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings of ($0.33) per share for the quarter, up from their previous forecast of ($0.38). Ascendiant Capital Markets currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($2.34) per share. Ascendiant Capital Markets also issued estimates for Cingulate’s Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.81) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.28) EPS, Q4 2027 earnings at ($0.28) EPS and FY2027 earnings at ($1.29) EPS.

Cingulate (NASDAQ:CING) last posted its earnings results on Thursday, May 14th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.42).

A number of other equities research analysts have also recently commented on the company. Roth Mkm restated a “buy” rating and set a $10.00 target price on shares of Cingulate in a research report on Tuesday, May 19th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Cingulate in a research report on Tuesday, May 26th. Weiss Ratings upgraded Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Wall Street Zen cut Cingulate from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

Cingulate Stock Up 5.2%

NASDAQ:CING opened at $4.89 on Thursday. Cingulate has a 52 week low of $3.16 and a 52 week high of $11.89. The stock has a market capitalization of $65.87 million, a PE ratio of -1.16 and a beta of -0.85. The stock’s 50-day moving average price is $5.08 and its 200-day moving average price is $5.41.

Institutional Investors Weigh In On Cingulate

Several institutional investors have recently bought and sold shares of CING. DRW Securities LLC acquired a new stake in Cingulate in the 4th quarter worth about $255,000. Renaissance Technologies LLC acquired a new stake in Cingulate in the 1st quarter worth about $198,000. Kestra Advisory Services LLC boosted its holdings in Cingulate by 29.8% in the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock worth $529,000 after buying an additional 27,979 shares during the last quarter. XTX Topco Ltd acquired a new stake in Cingulate in the 4th quarter worth about $90,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in Cingulate in the 1st quarter worth about $116,000. 41.31% of the stock is currently owned by institutional investors and hedge funds.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.